Circulating nucleic acids in plasma and serum (CNAPS): Applications in oncology

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 819-832

  González Masiá, José A ^a   García Olmo, Damián ^b   García Olmo, Dolores C ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

Author keywords

Biomarkers; Cancer; Clinical tool; Heterozygosity; microRNA; Plasma; Tumor suppressor genes; Viral genomic integration

Indexed keywords

CIRCULATING FREE DNA; CIRCULATING FREE RNA; CIRCULATING NUCLEIC ACID IN PLASMA AND SERUM; DNA; DNA FRAGMENT; MICRORNA; MITOCHONDRIAL DNA; NUCLEIC ACID; RNA; UNCLASSIFIED DRUG; VIRUS DNA;

CANCER GROWTH; CANCER PROGNOSIS; DNA DETERMINATION; DNA METHYLATION; EARLY DIAGNOSIS; GENE EXPRESSION; GENE MUTATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MICROSATELLITE MARKER; MOLECULAR DIAGNOSIS; MUTATIONAL ANALYSIS; NONHUMAN; PATIENT MONITORING; QUANTITATIVE ANALYSIS; REVIEW; RNA ANALYSIS;

EID: 84880097843     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S44668     Document Type: Review

References (173)

1. World Health Organization [homepage on the Internet]. Available from: http://www.who.int/features/qa/15/en/. Accessed June 6, 2013.
2. Jacobs EL, Haskell CM. Clinical use of tumor markers in oncology. Curr Probl Cancer. 1991;15(6):299-360.
3. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta. 2007;1775(1):181-232.
4. Mandel P, Métais P. Les acides nucléiques du plasma sanguin chez l'homme [The nucleic acids of blood plasma in humans]. Compte Rendu de l'Academie des Sciences. 1948;142:241-243. French.
5. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37(3): 646-650.
6. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 1989;46(5):318-322.
7. Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev. 1994;3(1):67-71.
8. Vasioukhin V, Anker P, Maurice P, Lyautey J, Lederrey C, Stroun M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol. 1994;86(4):774-779.
9. Jung K, Fleischhacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker-a critical appraisal of the literature. Clin Chim Acta. 2010;411(21-22):1611-1624.
10. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11(6):426-437.
11. Yu M. Somatic mitochondrial DNA mutations in human cancers. Adv Clin Chem. 2012;57:99-138.
12. Tsang JC, Lo YM. Circulating nucleic acids in plasma/serum. Pathology. 2007;39(2):197-207.
13. Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol. 2012;81(2):103-122.
14. Gahan PB, Anker P, Stroun M. Metabolic DNA as the origin of spontaneously released DNA? Ann N Y Acad Sci. 2008;1137:7-17.
15. Holdenrieder S, Stieber P, Bodenmüller H, etal. Circulating nucleosomes in serum. Ann N Y Acad Sci. 2001;945:93-102.
16. Holdenrieder S, Stieber P, Bodenmüller H, etal. Nucleosomes in serum as a marker for cell death. Clin Chem Lab Med. 2001;39(7):596-605.
17. Iguchi H, Kosaka N, Ochiya T. Secretory microRNAs as a versatile communication tool. Commun Integr Biol. 2010;3(5):478-481.
18. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654-659.
19. García-Olmo DC, García-Olmo D. Biological role of cell-free nucleic acids in cancer: the theory of genometastasis. Crit Rev Oncog. 2013;18(1-2):153-161.
20. Jahr S, Hentze H, Englisch S, etal. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61(4):1659-1665.
21. Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta. 2001;313(1-2):139-142.
22. Li CN, Hsu HL, Wu TL, Tsao KC, Sun CF, Wu JT. Cell-free DNA is released from tumor cells upon cell death: a study of tissue cultures of tumor cell lines. J Clin Lab Anal. 2003;17(4):103-107.
23. Choi JJ, Reich CF, Pisetsky DS. The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells. Immunology. 2005;115(1):55-62.
24. Stroun M, Maurice P, Vasioukhin V, etal. The origin and mechanism of circulating DNA. Ann N Y Acad Sci. 2000;906:161-168.
25. Thijssen MA, Swinkels DW, Ruers TJ, de Kok JB. Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases. Anticancer Res. 2002;22(1A):421-425.
26. Murtaza M, Dawson SJ, Tsui DW, etal. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013;497(7447):108-112.
27. Diehl F, Li M, Dressman D, etal. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005;102(45):16368-16373.
28. Giacona MB, Ruben GC, Iczkowski KA, Roos TB, Porter DM, Sorenson GD. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas. 1998;17(1):89-97.
29. Suzuki N, Kamataki A, Yamaki J, Homma Y. Characterization of circulating DNA in healthy human plasma. Clin Chim Acta. 2008;387(1-2): 55-58.
30. Holdenrieder S, Stieber P, Chan LY, etal. Cell-free DNA in serum and plasma: comparison of ELISA and quantitative PCR. Clin Chem. 2005;51(8):1544-1546.
31. Hasselmann DO, Rappl G, Tilgen W, Reinhold U. Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum. Clin Chem. 2001;47(8):1488-1489.
32. Cherepanova AV, Tamkovich SN, Bryzgunova OE, Vlassov VV, Laktionov PP. Deoxyribonuclease activity and circulating DNA concentration in blood plasma of patients with prostate tumors. Ann N Y Acad Sci. 2008;1137:218-221.
33. Frattini M, Gallino G, Signoroni S, etal. Quantitative analysis of plasma DNA in colorectal cancer patients: a novel prognostic tool. Ann N Y Acad Sci. 2006;1075:185-190.
34. Sozzi G, Conte D, Leon M, etal. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol. 2003;21(21): 3902-3908.
35. Szpechcinski A, Chorostowska-Wynimko J, Kupis W, etal. Quantitative analysis of free-circulating DNA in plasma of patients with resectable NSCLC. Expert Opin Biol Ther. 2012;12 Suppl 1:S3-S9.
36. Paci M, Maramotti S, Bellesia E, etal. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer. 2009;64(1):92-97.
37. Catarino R, Ferreira MM, Rodrigues H, etal. Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol. 2008;27(8):415-421.
38. Hashad D, Sorour A, Ghazal A, Talaat I. Free circulating tumor DNA as a diagnostic marker for breast cancer. J Clin Lab Anal. 2012;26(6): 467-472.
39. Sai S, Ichikawa D, Tomita H, etal. Quantification of plasma cell-free DNA in patients with gastric cancer. Anticancer Res. 2007;27(4C): 2747-2751.
40. Tomita H, Ichikawa D, Ikoma D, etal. Quantification of circulating plasma DNA fragments as tumor markers in patients with esophageal cancer. Anticancer Res. 2007;27(4C):2737-2741.
41. Shapiro B, Chakrabarty M, Cohn EM, Leon SA. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer. 1983;51(11):2116-2120.
42. Yoon KA, Park S, Lee SH, Kim JH, Lee JS. Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. J Mol Diagn. 2009;11(3):182-185.
43. Zhang R, Shao F, Wu X, Ying K. Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis. Lung Cancer. 2010;69(2):225-231.
44. Chang HW, Lee SM, Goodman SN, etal. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst. 2002;94(22):1697-1703.
45. Atamaniuk J, Vidotto C, Tschan H, Bachl N, Stuhlmeier KM, Müller MM. Increased concentrations of cell-free plasma DNA after exhaustive exercise. Clin Chem. 2004;50(9):1668-1670.
46. Laktionov PP, Tamkovich SN, Rykova EY, etal. Extracellular circulating nucleic acids in human plasma in health and disease. Nucleosides Nucleotides Nucleic Acids. 2004;23(6-7):879-883.
47. Lo YM, Rainer TH, Chan LY, Hjelm NM, Cocks RA. Plasma DNA as a prognostic marker in trauma patients. Clin Chem. 2000;46(3): 319-323.
48. Wu TL, Zhang D, Chia JH, Tsao K, Sun CF, Wu JT. Cell-free DNA: measurement in various carcinomas and establishment of normal reference range. Clin Chim Acta. 2002;321(1-2):77-87.
49. Lecomte T, Ceze N, Dorval E, Laurent-Puig P. Circulating free tumor DNA and colorectal cancer. Gastroenterol Clin Biol. 2010;34(12): 662-681.
50. García-Olmo DC, Samos J, Picazo MG, Asensio AI, Toboso I, García-Olmo D. Release of cell-free DNA into the bloodstream leads to high levels of non-tumor plasma DNA during tumor progression in rats. Cancer Lett. 2008;272(1):133-140.
51. García-Olmo DC, Picazo MG, Toboso I, Asensio AI, García-Olmo D. Quantitation of cell-free DNA and RNA in plasma during tumor progression in rats. Mol Cancer. 2013;12:8.
52. Agostini M, Pucciarelli S, Enzo MV, etal. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. Ann Surg Oncol. 2011;18(9):2461-2468.
53. Frattini M, Gallino G, Signoroni S, etal. Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett. 2008;263(2):170-181.
54. Holdenrieder S, Stieber P, von Pawel J, etal. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2004;10(18 Pt 1): 5981-5987.
55. Holdenrieder S, Nagel D, Schalhorn A, etal. Clinical relevance of circulating nucleosomes in cancer. Ann N Y Acad Sci. 2008;1137: 180-189.
56. Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res. 2007;635(2-3):105-117.
57. Wang BG, Huang HY, Chen YC, etal. Increased plasma DNA integrity in cancer patients. Cancer Res. 2003;63(14):3966-3968.
58. Umetani N, Kim J, Hiramatsu S, etal. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem. 2006;52(6): 1062-1069.
59. Umetani N, Giuliano AE, Hiramatsu SH, etal. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol. 2006;24(26):4270-4276.
60. Chen H, Sun LY, Zheng HQ, Zhang QF, Jin XM. Total serum DNA and DNA integrity: diagnostic value in patients with hepatitis B virus-related hepatocellular carcinoma. Pathology. 2012;44(4):318-324.
61. Jiang WW, Zahurak M, Goldenberg D, etal. Increased plasma DNA integrity index in head and neck cancer patients. Int J Cancer. 2006;119(11):2673-2676.
62. Pinzani P, Salvianti F, Zaccara S, etal. Circulating cell-free DNA in plasma of melanoma patients: qualitative and quantitative considerations. Clin Chim Acta. 2011;412(23-24):2141-2145.
63. Gao YJ, He YJ, Yang ZL, etal. Increased integrity of circulating cell-free DNA in plasma of patients with acute leukemia. Clin Chem Lab Med. 2010;48(11):1651-1656.
64. Chan KC, Leung SF, Yeung SW, Chan AT, Lo YM. Persistent aberrations in circulating DNA integrity after radiotherapy are associated with poor prognosis in nasopharyngeal carcinoma patients. Clin Cancer Res. 2008;14(13):4141-4145.
65. Casadio V, Calistri D, Tebaldi M, etal. Urine Cell-Free DNA integrity as a marker for early bladder cancer diagnosis: Preliminary data. Urol Oncol. 2012. Epub Nov 9.
66. Holdenrieder S, Burges A, Reich O, Spelsberg FW, Stieber P. DNA integrity in plasma and serum of patients with malignant and benign diseases. Ann N Y Acad Sci. 2008;1137:162-170.
67. Kopreski MS, Benko FA, Borys DJ, Khan A, McGarrity TJ, Gocke CD. Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. J Natl Cancer Inst. 2000;92(11):918-923.
68. Sorenson GD. A review of studies on the detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. Ann N Y Acad Sci. 2000;906:13-16.
69. Garcia JM, Silva JM, Dominguez G, Silva J, Bonilla F. Heterogeneous tumor clones as an explanation of discordance between plasma DNA and tumor DNA alterations. Genes Chromosomes Cancer. 2001;31(3): 300-301.
70. Maire F, Micard S, Hammel P, etal. Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA. Br J Cancer. 2002;87(5): 551-554.
71. Castells A, Puig P, Móra J, etal. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J Clin Oncol. 1999;17(2):578-584.
72. Gormally E, Vineis P, Matullo G, etal. TP53 and KRAS2mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. Cancer Res. 2006;66(13):6871-6876.
73. Chen Z, Feng J, Buzin CH, etal. Analysis of cancer mutation signatures in blood by a novel ultra-sensitive assay: monitoring of therapy or recurrence in non-metastatic breast cancer. PLoS One. 2009;4(9):e7220.
74. Diehl F, Schmidt K, Choti MA, etal. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985-990.
75. Levy M, Benesova L, Lipska L, etal. Utility of cell-free tumour DNA for post-surgical follow-up of colorectal cancer patients. Anticancer Res. 2012;32(5):1621-1626.
76. Ryan BM, Lefort F, McManus R, etal. A prospective study of circulating mutant KRAS2in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up. Gut. 2003;52(1):101-108.
77. Page K, Hava N, Ward B, etal. Detection of HER2 amplification in circulating free DNA in patients with breast cancer. Br J Cancer. 2011;104(8):1342-1348.
78. Dawson SJ, Tsui DW, Murtaza M, etal. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368(13): 1199-1209.
79. Gadgeel SM, Cote ML, Schwartz AG, Matherly LH, Wozniak A, Bepler G. Parameters for individualizing systemic therapy in non-small cell lung cancer. Drug Resist Updat. 2010;13(6):196-204.
80. Rosell R, Vergnenegre A, Liu B, etal. Biomarkers in lung oncology. Pulm Pharmacol Ther. 2010;23(6):508-514.
81. Mack PC, Holland WS, Burich RA, etal. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol. 2009;4(12):1466-1472.
82. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 1999;59(1):67-70.
83. Lo YM, Wong IH, Zhang J, Tein MS, Ng MH, Hjelm NM. Quantitative analysis of aberrant p16methylation using real-time quantitative methylation-specific polymerase chain reaction. Cancer Res. 1999;59(16):3899-3903.
84. Casciano I, Vinci AD, Banelli B, etal. Circulating tumor nucleic acids: perspective in breast Cancer. Breast care (Basel). 2010;5(2):75-80.
85. Radpour R, Barekati Z, Kohler C, etal. Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLoS One. 2011; 6(1):e16080.
86. Wong IH, Lo YM, Zhang J, etal. Detection of aberrant p16methylation in the plasma and serum of liver cancer patients. Cancer Res. 1999;59(1):71-73.
87. Silva JM, Dominguez G, Villanueva MJ, etal. Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients. Br J Cancer. 1999;80(8):1262-1264.
88. Tsutsui M, Iizuka N, Moribe T, etal. Methylated cyclin D2gene circulating in the blood as a prognosis predictor of hepatocellular carcinoma. Clin Chim Acta. 2010;411(7-8):516-520.
89. Ling ZQ, Zhao Q, Zhou SL, Mao WM. MSH2 promoter hypermethylation in circulating tumor DNA is a valuable predictor of disease-free survival for patients with esophageal squamous cell carcinoma. Eur J Surg Oncol. 2012;38(4):326-332.
90. Goessl C, Müller M, Straub B, Miller K. DNA alterations in body fluids as molecular tumor markers for urological malignancies. Eur Urol. 2002;41(6):668-676.
91. Iriyama C, Tomita A, Hoshino H, etal. Using peripheral blood circulating DNAs to detect CpG global methylation status and genetic mutations in patients with myelodysplastic syndrome. Biochem Biophys Res Commun. 2012;419(4):662-669.
92. Fiegl H, Millinger S, Mueller-Holzner E, etal. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res. 2005;65(4):1141-1145.
93. Schwarzenbach H, Müller V, Stahmann N, Pantel K. Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer. Ann N Y Acad Sci. 2004;1022:25-32.
94. Sunami E, Shinozaki M, Higano CS, etal. Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin Chem. 2009;55(3):559-567.
95. Hamana K, Uzawa K, Ogawara K, etal. Monitoring of circulating tumour-associated DNA as a prognostic tool for oral squamous cell carcinoma. Br J Cancer. 2005;92(12):2181-2184.
96. Schwarzenbach H, Müller V, Milde-Langosch K, Steinbach B, Pantel K. Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease. Mol Biosyst. 2011;7(10): 2848-2854.
97. Garcia JM, Garcia V, Silva J, etal. Extracellular tumor DNA in plasma and overall survival in breast cancer patients. Genes Chromosomes Cancer. 2006;45(7):692-701.
98. Taback B, O'Day SJ, Boasberg PD, etal. Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma. J Natl Cancer Inst. 2004;96(2): 152-156.
99. Chan KC, Lo YM. Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers. Br J Cancer. 2007;96(5):681-685.
100. Jones K, Nourse JP, Keane C, etal. Tumor-specific but not nonspecific cell-free circulating DNA can be used to monitor disease response in lymphoma. Am J Hematol. 2012;87(3):258-265.
101. Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM. Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. Br J Haematol. 2000;111(1):239-246.
102. Lo YM, Chan WY, Ng EK, etal. Circulating Epstein-Barr virus DNA in the serum of patients with gastric carcinoma. Clin Cancer Res. 2001;7(7):1856-1859.
103. Lo YM. Prognostic implication of pretreatment plasma/serum concentration of Epstein-Barr virus DNA in nasopharyngeal carcinoma. Biomed Pharmacother. 2001;55(7):362-365.
104. Fliss MS, Usadel H, Caballero OL, etal. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science. 2000;287(5460):2017-2019.
105. Xia P, An HX, Dang CX, etal. Decreased mitochondrial DNA content in blood samples of patients with stage I breast cancer. BMC Cancer. 2009;9:454.
106. Mithani SK, Smith IM, Zhou S, etal. Mitochondrial resequencing arrays detect tumor-specific mutations in salivary rinses of patients with head and neck cancer. Clin Cancer Res. 2007;13(24):7335-7340.
107. Jerónimo C, Nomoto S, Caballero OL, etal. Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene. 2001;20(37):5195-5198.
108. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8(6):519-530.
109. Chiu RW, Chan LY, Lam NY, etal. Quantitative analysis of circulating mitochondrial DNA in plasma. Clin Chem. 2003;49(5):719-726.
110. Lee HC, Chang CM, Chi CW. Somatic mutations of mitochondrial DNA in aging and cancer progression. Ageing Res Rev. 2010;9 Suppl 1:S47-S58.
111. Copeland WC, Wachsman JT, Johnson FM, Penta JS. Mitochondrial DNA alterations in cancer. Cancer Invest. 2002;20(4):557-569.
112. Okochi O, Hibi K, Uemura T, etal. Detection of mitochondrial DNA alterations in the serum of hepatocellular carcinoma patients. Clin Cancer Res. 2002;8(9):2875-2878.
113. Kassauei K, Habbe N, Mullendore ME, Karikari CA, Maitra A, Feldmann G. Mitochondrial DNA mutations in pancreatic cancer. Int J Gastrointest Cancer. 2006;37(2-3):57-64.
114. Mehra N, Penning M, Maas J, van Daal N, Giles RH, Voest EE. Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer. Clin Cancer Res. 2007;13(2 Pt 1):421-426.
115. Hibi K, Nakayama H, Yamazaki T, etal. Mitochondrial DNA alteration in esophageal cancer. Int J Cancer. 2001;92(3):319-321.
116. Hibi K, Nakayama H, Yamazaki T, etal. Detection of mitochondrial DNA alterations in primary tumors and corresponding serum of colorectal cancer patients. Int J Cancer. 2001;94(3):429-431.
117. Kohler C, Radpour R, Barekati Z, etal. Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer. 2009;8:105.
118. Zachariah RR, Schmid S, Buerki N, Radpour R, Holzgreve W, Zhong X. Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors. Obstet Gynecol. 2008;112(4):843-850.
119. Ellinger J, Müller DC, Müller SC, etal. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies. Urol Oncol. 2012;30(4):509-515.
120. Wieczorek AJ, Sitaramam V, Machleidt W, Rhyner K, Perruchoud AP, Block LH. Diagnostic and prognostic value of RNA-proteolipid in sera of patients with malignant disorders following therapy: first clinical evaluation of a novel tumor marker. Cancer Res. 1987;47(23): 6407-6412.
121. Lässer C, Alikhani VS, Ekström K, etal. Human saliva, plasma and breast milk exosomes contain RNA: uptake by macrophages. J Transl Med. 2011;9:9.
122. Kopreski MS, Benko FA, Kwak LW, Gocke CD. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin Cancer Res. 1999;5(8):1961-1965.
123. Lo KW, Lo YM, Leung SF, etal. Analysis of cell-free Epstein-Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma. Clin Chem. 1999;45(8 Pt 1):1292-1294.
124. Dasí F, Lledó S, García-Granero E, etal. Real-time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA: a simple blood test to monitor disease in cancer patients. Lab Invest. 2001;81(5):767-769.
125. Silva JM, Rodriguez R, Garcia JM, etal. Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Gut. 2002;50(4):530-534.
126. Lledó SM, Garcia-Granero E, Dasí F, etal. Real time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA in patients with colorectal cancer. Colorectal Dis. 2004;6(4):236-242.
127. Silva JM, Dominguez G, Silva J, etal. Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. Clin Cancer Res. 2001;7(9): 2821-2825.
128. Chen XQ, Bonnefoi H, Pelte MF, etal. Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res. 2000;6(10):3823-3826.
129. Dasí F, Martínez-Rodes P, March JA, etal. Real-time quantification of human telomerase reverse transcriptase mRNA in the plasma of patients with prostate cancer. Ann N Y Acad Sci. 2006;1075:204-210.
130. March-Villalba JA, Martínez-Jabaloyas JM, Herrero MJ, Santamaría J, Aliño SF, Dasí F. Plasma hTERT mRNA discriminates between clinically localized and locally advanced disease and is a predictor of recurrence in prostate cancer patients. Expert Opin Biol Ther. 2012;12 Suppl 1:S69-S77.
131. Kopreski MS, Benko FA, Gocke CD. Circulating RNA as a tumor marker: detection of 5T4mRNA in breast and lung cancer patient serum. Ann N Y Acad Sci. 2001;945:172-178.
132. Chinnappa P, Taguba L, Arciaga R, etal. Detection of thyrotropin-receptor messenger ribonucleic acid (mRNA) and thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease: sensitive and specific markers for thyroid cancer. J Clin Endocrinol Metab. 2004;89(8):3705-3709.
133. Reddi KK, Holland JF. Elevated serum ribonuclease in patients with pancreatic cancer. Proc Natl Acad Sci U S A. 1976;73(7):2308-2310.
134. Tsui NB, Ng EK, Lo YM. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin Chem. 2002;48(10):1647-1653.
135. Ng EK, Tsui NB, Lam NY, etal. Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy individuals. Clin Chem. 2002;48(8):1212-1217.
136. Tzimagiorgis G, Michailidou EZ, Kritis A, Markopoulos AK, Kouidou S. Recovering circulating extracellular or cell-free RNA from bodily fluids. Cancer Epidemiol. 2011;35(6):580-589.
137. Terrin L, Rampazzo E, Pucciarelli S, etal. Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease. Clin Cancer Res. 2008;14(22):7444-7451.
138. Miura N, Nakamura H, Sato R, etal. Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. Cancer Sci. 2006;97(12):1366-1373.
139. Miura N, Maruyama S, Oyama K, etal. Development of a novel assay to quantify serum human telomerase reverse transcriptase messenger RNA and its significance as a tumor marker for hepatocellular carcinoma. Oncology. 2007;72 Suppl 1:45-51.
140. Pucciarelli S, Rampazzo E, Briarava M, etal. Telomere-specific reverse transcriptase (hTERT) and cell-free RNA in plasma as predictors of pathologic tumor response in rectal cancer patients receiving neoadjuvant chemoradiotherapy. Ann Surg Oncol. 2012;19(9):3089-3096.
141. El-Hefnawy T, Raja S, Kelly L, etal. Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem. 2004;50(3):564-573.
142. El-Abd E, El-Tahan R, Fahmy L, etal. Serum metastasin mRNA is an important survival predictor in breast cancer. Br J Biomed Sci. 2008;65(2):90-94.
143. Fleischhacker M, Beinert T, Ermitsch M, etal. Detection of amplifiable messenger RNA in the serum of patients with lung cancer. Ann N Y Acad Sci. 2001;945:179-188.
144. Honma H, Kanda T, Ito H, etal. Squamous cell carcinoma-antigen messenger RNA level in peripheral blood predicts recurrence after resection in patients with esophageal squamous cell carcinoma. Surgery. 2006;139(5):678-685.
145. Dong ZZ, Yao DF, Yao M, etal. Clinical impact of plasma TGF-beta1 and circulating TGF-beta1mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2008;7(3):288-295.
146. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009;27(34):5848-5856.
147. Chen X, Ba Y, Ma L, etal. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997-1006.
148. Ng EK, Chong WW, Jin H, etal. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009;58(10):1375-1381.
149. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010;127(1):118-126.
150. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010;101(10):2087-2092.
151. Hu Z, Chen X, Zhao Y, etal. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010;28(10):1721-1726.
152. Wang ZX, Bian HB, Wang JR, Cheng ZX, Wang KM, De W. Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer. J Surg Oncol. 2011;104(7):847-851.
153. Liu XG, Zhu WY, Huang YY, etal. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol. 2012;29(2):618-626.
154. Roth C, Stückrath I, Pantel K, Izbicki JR, Tachezy M, Schwarzenbach H. Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors. PLoS One. 2012;7(6):e38248.
155. Wang F, Zheng Z, Guo J, Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol. 2010;119(3):586-593.
156. Mitchell PS, Parkin RK, Kroh EM, etal. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513-10518.
157. Bandres E, Bitarte N, Arias F, etal. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res. 2009;15(7):2281-2290.
158. Yang H, Gu J, Wang KK, etal. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res. 2009;15(18):5744-5752.
159. Lawrie CH, Gal S, Dunlop HM, etal. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141(5):672-675.
160. Zandberga E, Kozirovskis V, Ābols A, Andrējeva D, Purkalne G, Linē A. Cell-free microRNAs as diagnostic, prognostic, and predictive biomarkers for lung cancer. Genes Chromosomes Cancer. 2013;52(4):356-369.
161. Lu J, Getz G, Miska EA, etal. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834-838.
162. Rosenfeld N, Aharonov R, Meiri E, etal. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 2008;26(4):462-469.
163. Weber JA, Baxter DH, Zhang S, etal. The microRNA spectrum in 12 body fluids. Clin Chem. 2010;56(11):1733-1741.
164. Xie L, Qian X, Liu B. MicroRNAs: novel biomarkers for gastrointestinal carcinomas. Mol Cell Biochem. 2010;341(1-2):291-299.
165. Mo MH, Chen L, Fu Y, Wang W, Fu SW. Cell-free Circulating miRNA Biomarkers in Cancer. J Cancer. 2012;3:432-448.
166. Tokarz P, Blasiak J. The role of microRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment. Acta Biochim Pol. 2012;59(4):467-474.
167. Mattocks CJ, Morris MA, Matthijs G, etal. A standardized framework for the validation and verification of clinical molecular genetic tests. Eur J Hum Genet. 2010;18(12):1276-1288.
168. García-Olmo D, García-Olmo DC, Ontañón J, Martinez E, Vallejo M. Tumor DNA circulating in the plasma might play a role in metastasis. The hypothesis of the genometastasis. Histol Histopathol. 1999;14(4): 1159-1164.
169. García-Olmo DC, Domínguez C, García-Arranz M, etal. Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells. Cancer Res. 2010;70(2):560-567.
170. García-Olmo D, García-Olmo DC, Domínguez-Berzosa C, Guadalajara H, Vega L, García-Arranz M. Oncogenic transformation induced by cell-free nucleic acids circulating in plasma (genometastasis) remains after the surgical resection of the primary tumor: a pilot study. Expert Opin Biol Ther. 2012;12 Suppl 1:S61-S68.
171. Silva J, Garcia V, Rodriguez M, etal. Analysis of exosome release and its prognostic value in human colorectal cancer. Genes Chromosomes Cancer. 2012;51(4):409-418.
172. Mittelbrunn M, Gutiérrez-Vázquez C, Villarroya-Beltri C, etal. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun. 2011;2:282.
173. Peinado H, Alečković M, Lavotshkin S, etal. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012;18(6):883-891.